Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review

Advisory committee to discuss data on abuse of Opana ER and generic oxymorphone extended-release and immediate-release products.

FDA entrance sign 2016

An US FDA advisory committee is taking a closer look at the safety of one class of opioids: oxymorphone.

The agency announced in a Federal Register notice set for publication Jan. 11 that its Drug Safety and Risk Management...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers